Sr Sailor-
You raise a good point - I don't know why the Nabid study was never published. The
Nabid abstract appeared in 2013. It showed 18 months was as good as 36 months in high risk patients. It also included whole pelvic RT.
The latest study was DART 01/05, which proved that 28 months was better than 4 months, reinforcing the finding of RTOG 9202. EORTC 22961 also showed that 36 months was better than 6 months. On the other hand, TROG 03.04 RADAR found no difference between 6 months and 18 months, but they only used 66 Gy, which was probably inadequate treatment.
So my feeling is that with adequate treatment to the prostate and possibly the lymph nodes (where probability is high), 18-28 months of adjuvant ADT for high risk treated with IMRT is the right range. Eventually, we'll have better data.
-Allen